Modulation of gastrointestinal motility beyond metoclopramide and domperidone: Pharmacological and clinical evidence for phytotherapy in functional gastrointestinal disorders

The prokinetic cisapride, an important therapeutic option in functional gastrointestinal (GI) disorders, was withdrawn from the market 15 years ago due to rare severe side effects. Likewise in 2014, the use of metoclopramide (MCP) and domperidone in functional GI disorders (FGID) was restricted, con...

Descripción completa

Detalles Bibliográficos
Autores principales: Madisch, Ahmed, Vinson, Bettina R., Abdel-Aziz, Heba, Kelber, Olaf, Nieber, Karen, Kraft, Karin, Storr, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Vienna 2017
Materias:
Main Topic
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5409921/
https://www.ncbi.nlm.nih.gov/pubmed/28424994
http://dx.doi.org/10.1007/s10354-017-0557-3
_version_ 1783232563414827008
author Madisch, Ahmed
Vinson, Bettina R.
Abdel-Aziz, Heba
Kelber, Olaf
Nieber, Karen
Kraft, Karin
Storr, Martin
author_facet Madisch, Ahmed
Vinson, Bettina R.
Abdel-Aziz, Heba
Kelber, Olaf
Nieber, Karen
Kraft, Karin
Storr, Martin
author_sort Madisch, Ahmed
collection PubMed
description The prokinetic cisapride, an important therapeutic option in functional gastrointestinal (GI) disorders, was withdrawn from the market 15 years ago due to rare severe side effects. Likewise in 2014, the use of metoclopramide (MCP) and domperidone in functional GI disorders (FGID) was restricted, consequently leaving a therapeutic gap in clinical practice. A systematic review revealed that the herbal medicinal product (HMP) STW 5 presents a therapeutic option equivalent to MCP and cisapride. STW 5 is the only HMP for which efficacy has been shown in randomized controlled clinical trials (RCTs) in functional dyspepsia and irritable bowel syndrome, based on its multitarget effect on numerous etiological factors. Due to an outstanding favorable safety profile, STW 5 allows an effective and safe use in FGID without a limitation of the duration of the treatment.
format Online
Article
Text
id pubmed-5409921
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Springer Vienna
record_format MEDLINE/PubMed
spelling pubmed-54099212017-05-15 Modulation of gastrointestinal motility beyond metoclopramide and domperidone: Pharmacological and clinical evidence for phytotherapy in functional gastrointestinal disorders Madisch, Ahmed Vinson, Bettina R. Abdel-Aziz, Heba Kelber, Olaf Nieber, Karen Kraft, Karin Storr, Martin Wien Med Wochenschr Main Topic The prokinetic cisapride, an important therapeutic option in functional gastrointestinal (GI) disorders, was withdrawn from the market 15 years ago due to rare severe side effects. Likewise in 2014, the use of metoclopramide (MCP) and domperidone in functional GI disorders (FGID) was restricted, consequently leaving a therapeutic gap in clinical practice. A systematic review revealed that the herbal medicinal product (HMP) STW 5 presents a therapeutic option equivalent to MCP and cisapride. STW 5 is the only HMP for which efficacy has been shown in randomized controlled clinical trials (RCTs) in functional dyspepsia and irritable bowel syndrome, based on its multitarget effect on numerous etiological factors. Due to an outstanding favorable safety profile, STW 5 allows an effective and safe use in FGID without a limitation of the duration of the treatment. Springer Vienna 2017-04-19 2017 /pmc/articles/PMC5409921/ /pubmed/28424994 http://dx.doi.org/10.1007/s10354-017-0557-3 Text en © The Author(s) 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Main Topic
Madisch, Ahmed
Vinson, Bettina R.
Abdel-Aziz, Heba
Kelber, Olaf
Nieber, Karen
Kraft, Karin
Storr, Martin
Modulation of gastrointestinal motility beyond metoclopramide and domperidone: Pharmacological and clinical evidence for phytotherapy in functional gastrointestinal disorders
title Modulation of gastrointestinal motility beyond metoclopramide and domperidone: Pharmacological and clinical evidence for phytotherapy in functional gastrointestinal disorders
title_full Modulation of gastrointestinal motility beyond metoclopramide and domperidone: Pharmacological and clinical evidence for phytotherapy in functional gastrointestinal disorders
title_fullStr Modulation of gastrointestinal motility beyond metoclopramide and domperidone: Pharmacological and clinical evidence for phytotherapy in functional gastrointestinal disorders
title_full_unstemmed Modulation of gastrointestinal motility beyond metoclopramide and domperidone: Pharmacological and clinical evidence for phytotherapy in functional gastrointestinal disorders
title_short Modulation of gastrointestinal motility beyond metoclopramide and domperidone: Pharmacological and clinical evidence for phytotherapy in functional gastrointestinal disorders
title_sort modulation of gastrointestinal motility beyond metoclopramide and domperidone: pharmacological and clinical evidence for phytotherapy in functional gastrointestinal disorders
topic Main Topic
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5409921/
https://www.ncbi.nlm.nih.gov/pubmed/28424994
http://dx.doi.org/10.1007/s10354-017-0557-3
work_keys_str_mv AT madischahmed modulationofgastrointestinalmotilitybeyondmetoclopramideanddomperidonepharmacologicalandclinicalevidenceforphytotherapyinfunctionalgastrointestinaldisorders
AT vinsonbettinar modulationofgastrointestinalmotilitybeyondmetoclopramideanddomperidonepharmacologicalandclinicalevidenceforphytotherapyinfunctionalgastrointestinaldisorders
AT abdelazizheba modulationofgastrointestinalmotilitybeyondmetoclopramideanddomperidonepharmacologicalandclinicalevidenceforphytotherapyinfunctionalgastrointestinaldisorders
AT kelberolaf modulationofgastrointestinalmotilitybeyondmetoclopramideanddomperidonepharmacologicalandclinicalevidenceforphytotherapyinfunctionalgastrointestinaldisorders
AT nieberkaren modulationofgastrointestinalmotilitybeyondmetoclopramideanddomperidonepharmacologicalandclinicalevidenceforphytotherapyinfunctionalgastrointestinaldisorders
AT kraftkarin modulationofgastrointestinalmotilitybeyondmetoclopramideanddomperidonepharmacologicalandclinicalevidenceforphytotherapyinfunctionalgastrointestinaldisorders
AT storrmartin modulationofgastrointestinalmotilitybeyondmetoclopramideanddomperidonepharmacologicalandclinicalevidenceforphytotherapyinfunctionalgastrointestinaldisorders

Ejemplares similares